Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Gold/Mining/Energy : Inflazyme Pharmaceuticals (T.IZP) -- Ignore unavailable to you. Want to Upgrade?

To: Harold Lehman who wrote (805)	1/24/1998 10:56:00 PM
From: Harold Engstrom	Read Replies (1) \| Respond to of 1501

I guess the only thing to do is call IR. VLA-4 is to be tried on inflammatory and autoimmune disorders. MS has to do with inflammation of the myelin sheath. Asthma is another inflammatory indication. In order to see what is going on with most companies, beyond what what is deliberately worded, one needs to try to link various statements from different sources together. I may be totally wrong, but I think that what Dr. Davies said at the annual meeting, combined with what has been said previously about VLA-4 and what Jim Tobin said in the last conference call, indicates that VLA-4 may be administered either orally or by inhalation. I am not stating definitively that that is the case, just that my opinion is such - based on the information that I've heard or read.